A combination efficacy study in Africa of two DNA-MVA- or DNA- Env protein HIV-1 vaccine regimens with pre-exposure prophylaxis
A combination efficacy study in Africa of two DNA-MVA- or DNA- Env protein HIV-1 vaccine regimens with pre-exposure prophylaxis (PrEPVacc) is a project supported by European and Developing Countries Clinical Trials Partnership (EDCTP). It is an African-led European-supported HIV prevention phase IIB study running in East and Southern Africa. For the first time, it is combining evaluation of experimental HIV vaccines and pre-exposure prophylaxis (PrEP) at the same time. PrEPVacc will compare DNA-MVA-protein with DNA-protein immunisation; and explore universal PrEP in an HIV vaccine study population. Its adaptive trial design is novel in the HIV vaccine field and will generate data on HIV vaccine efficacy and investigate correlates of protection, address adherence and attitudes to PrEP and its impact on HIV vaccine trial.
PrEPVacc is coordinated by Imperial College London, UK. EVF provides one of the experimental vaccine candidates (DNA-HIV-PT123 vaccine) under evaluation in the trial.
For more information, visit website